Literature DB >> 10523715

Advances in the molecular genetics of endometrial cancer (Review).

M Esteller1, J Xercavins, J Reventos.   

Abstract

Recent studies have identified some of the genetic alterations involved in endometrial carcinoma development. Transforming genes, including K-ras and c-erbB2/neu oncogenes and the p53, PTEN and hMLH1 tumor suppressor genes, are the most frequently altered. In addition, endometrial carcinomas express high levels of chemoresistance markers, including the MDR-1 or the MRP genes. The genetic background of an endometrial cancer patient may include high-penetrance genes such as the DNA mismatch repair genes causing microsatellite instability, and low-penetrance genes such as those involved in estrogen-metabolism. The spectrum of several molecular lesions suggest a model for endometrial tumorigenesis through two divergent pathways, and which may improve the design of more rational therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10523715     DOI: 10.3892/or.6.6.1377

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Expression of PTTG1 and PTEN in endometrial carcinoma: correlation with tumorigenesis and progression.

Authors:  Zhen-Zhong Feng; Jia-Wei Chen; Zhao-Rui Yang; Guang-Zhong Lu; Zhao-Gen Cai
Journal:  Med Oncol       Date:  2010-12-22       Impact factor: 3.064

2.  Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines.

Authors:  Chung-Pu Wu; Cheng-Yu Hung; Sabrina Lusvarghi; Yang-Hui Huang; Pin-Jung Tseng; Tai-Ho Hung; Jau-Song Yu; Suresh V Ambudkar
Journal:  Biochem Pharmacol       Date:  2020-07-04       Impact factor: 5.858

3.  Oviduct-specific glycoprotein is a molecular marker for invasion in endometrial tumorigenesis identified using a relevant mouse model.

Authors:  Hong Wang; Ayesha Joshi; Lori Iaconis; Garron J Solomon; Zhaoying Xiang; Harold G Verhage; Wayne Douglas; Brigitte M Ronnett; Lora Hedrick Ellenson
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

Review 4.  Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents.

Authors:  Katherine M Moxley; D Scott McMeekin
Journal:  Oncologist       Date:  2010-10-07

5.  Circulating miRNA 27a and miRNA150-5p; a noninvasive approach to endometrial carcinoma.

Authors:  Rasha Abdelmawla Ghazala; Eman Ahmed El-Attar; Ziad Sami Abouzeid
Journal:  Mol Biol Rep       Date:  2021-06-02       Impact factor: 2.316

6.  Association between RCAS1 expression and clinical outcome in uterine endometrial cancer.

Authors:  K Sonoda; S Miyamoto; T Hirakawa; T Kaku; M Nakashima; T Watanabe; K Akazawa; T Fujita; H Nakano
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.